Member Info for shares123

It is encouraging that they have applied for a patent. Along with the test working among a diverse ethnic groups.

Once they get FDA approval for the test they will make alot in America.

I use Jarvis Investment Management plateform to buy EDX

https://www.x-o.co.uk

"consideration of progression to other public markets including the AIM market in London and a Hong Kong listing"

"The Company is in the process of trying to secure material producing assets. Whilst the likelihood remained uncertain, a

successful outcome may warrant the Company to make a bid deposit within a short time frame and

therefore it would be impractical for the Company to apply for additional headroom at a later stage."

Https://youtu.be/JXcQozX5YV4?si=A4lRXUWK32JjJpnQ

https://hardmanandco.com/wp-content/uploads/2024/11/EDX-Medical-Hardman-Co-Nov-2024.pdf

The predominantly non-cash loss before tax of £18.2 million was primarily due to

an accounting impairment charge on goodwill of £15.8 million, arising from the

revaluation of goodwill in respect of the 2023 investment in the Company's

subsidiaries.

After Ischemic Stroke Bioventix Anti-Tau antibody is correlated with Ischemic stroke. New big market.

https://www.bioventix.com/association-of-plasma-brain-derived-tau-with-functional-outcome-after-ischemic-stroke/

Https://neurosciencenews.com/uk-alzheimers-blood-test-25867/

Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10916963/

The new Tau test is from Alzpath (https://alzpath.bio/about/)

Shows university of Gothenburg is a partner in the evaluation.

Is the new p-tau217 test using Bioventix antibodies. Even if not, it is good news for Bioventix p-tau217 new assay for Alzheimer's.

https://www.bbc.co.uk/news/health-68726703

https://www.med-technews.com/news/Medtech-Diagnostics-news/sensyne-and-excalibur-sign-lateral-flow-diagnostics-deal/

https://www.edxmedical.co.uk/

https://www.nature.com/articles/nbt0602supp-BE13

https://www.youtube.com/watch?v=SR14CvVb4LI

Maxcyte is like Abzena. I remember Abzena also had a high cash burn rate, was loss making and had lots of licences for royalties on the drugs that got to market by their customers. The market cap was continously eaten away untill it was bought out for a fraction of its value.

I think this could happen here.

8% of £13.7 million over three years is 3.288M profit. That is the same as the market cap at suspension!

x25 earnings is a little high if the growth has stalled (NT-proBNP: £1.28 million has now permanently gone from the revenue stream).
Hopefully, they can get some extra revenue from other sources than just the troponin antibody to make up for the shortfall.

Hi Rooky,
With the new results the P/E goes down to 27. Very reasonable considering it has strong growth and it is not affected by the slow down to much. Not to mention the special dividend and dividend. I make that 141p for the year and a 3.3% div yield.

This is the sort of share to buy and hold. Also the total issued shares has not changed by much for the last 5 years. So you are not getting diluted for this growth.

Wonderfull results I have bought back in. The growth has been from the T3 and anti- drug testing antibody in the UK and rest of the world/china. From R&D projects and product revenue. It seems whenever they can see a revenue drop (e.g. testosterone/estradiol/NT-proBNP) testing they seem to be able to go out and get new R&D projects from their partners to fill the revenue gap. Anti-Troponin antibody role out is very slow but it is building.